Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 2/2013

01-10-2013 | Original Paper

Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study

Authors: Archana Krishnan, Jeffrey A. Wickersham, Ehsan Chitsaz, Sandra A. Springer, Alison O. Jordan, Nick Zaller, Frederick L. Altice

Published in: AIDS and Behavior | Special Issue 2/2013

Login to get access

Abstract

HIV-infected individuals with substance use disorders have a high prevalence of medical and psychiatric morbidities that complicate treatment. Incarceration further disrupts healthcare access and utilization. Without appropriate diagnosis and treatment, drug relapse upon release exceeds 85 %, which contributes to poor health outcomes. A prospective cohort of 1,032 HIV-infected jail detainees were surveyed in a ten-site demonstration project during incarceration and six-months post-release, in order to examine the effect of predisposing factors, enabling resources and need factors on their subsequent drug use. Homelessness, pre-incarceration cocaine and opioid use, and high drug and alcohol severity were significantly associated with cocaine and opioid relapse. Substance abuse treatment, though poorly defined, did not influence post-release cocaine and opioid use. An approach that integrates multiple services, simultaneously using evidence-based substance abuse, psychiatric care, and social services is needed to improve healthcare outcomes for HIV-infected persons transitioning from jails to the community.
Literature
1.
Sabol WJ, Minton TD. Jail inmates at midyear 2007. DC: Washington; 2008.
2.
West H, Sabol W. Prisoners in 2007. Washington, DC: Bureau of Justice Statistics Bulletin (NCJ224280); 2008.
3.
Warren J, Gelb A, Horowitz J, Riordan J. One in 100: behind bars in America 2008. Washington, DC: The Pew Charitable Trusts, Public Safety Performance Project; 2008.
4.
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558.PubMedCrossRef
5.
Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92(11):1789–94.PubMedCrossRef
6.
7.
Schwarcz SK, Hsu LC, Vittinghoff E, Vu A, Bamberger JD, Katz MH. Impact of housing on the survival of persons with AIDS. BMC Public Health. 2009;9:220.PubMedCrossRef
8.
Williams BA, McGuire J, Lindsay RG, et al. Coming home: health status and homelessness risk of older pre-release prisoners. J Gen Intern Med. 2010;25(10):1038–44.PubMedCrossRef
9.
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications of adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis. 2011;53(5):469–79.PubMedCrossRef
10.
Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. JAMA. 2009;301(8):848–57.PubMedCrossRef
11.
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754–60.PubMedCrossRef
12.
Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84–8.PubMed
13.
Stephenson BL, Wohl DA, McKaig R, et al. Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS. 2006;17(2):103–8.PubMedCrossRef
14.
MacGowan RJ, Margolis A, Gaiter J, et al. Predictors of risky sex of young men after release from prison. Int J STD AIDS. 2003;14(8):519–23.PubMedCrossRef
15.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.PubMedCrossRef
16.
Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.PubMed
17.
Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.PubMed
18.
Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011;8(4):223–34.PubMedCrossRef
19.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months post release. J Subst Abuse Treat. 2009;37(3):277–85.PubMedCrossRef
20.
Braithwaite RL, Arriola KR. Male prisoners and HIV prevention: a call for action ignored. Am J Public Health. 2003;93(5):759–63.PubMedCrossRef
21.
22.
Flanigan TP, Zaller N, Beckwith CG, et al. Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S78–83.PubMedCrossRef
23.
de Voux A, Spaulding AC, Beckwith C, et al. Early identification of HIV: Empirical support for jail-based screening. PLoS ONE. 2012;7(5):e37603.PubMedCrossRef
24.
White MC, Tulsky JP, Estes M, Jamison R, Long HL. Health and health behaviors in HIV-infected jail inmates, 1999 and 2005. AIDS Patient Care STDS. 2008;22(3):221–31.PubMedCrossRef
25.
Draine J, Ahuja D, Altice FL, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care. 2011;23(3):366–77.PubMedCrossRef
26.
Althoff AL, Zelenev AL, Meyer JP, et al. Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav. 2012. doi:10.​1007/​s10461-012-0372-1.
27.
Office of National Drug Control Policy. ADAM II: 2011 Annual Report, Arrestee Drug Abuse Monitoring Program. Washington, DC: Office of National Drug Control Policy. May 2010.
28.
Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1–10.PubMedCrossRef
29.
Gelberg L, Andersen RM, Leake BD. The Behavioral Model for Vulnerable Populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273–302.PubMed
30.
McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):14.CrossRef
31.
Rikoon SH, Cacciola JS, Carise D, Alterman AI, McLellan AT. Predicting DSM-IV dependence diagnoses from Addiction Severity Index composite scores. J Subst Abuse Treat. 2006;31(1):17–24.PubMedCrossRef
32.
Calsyn DA, Saxon AJ, Bush KR, et al. The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. Drug Alcohol Depend. 2004;76(2):165–71.PubMedCrossRef
33.
McLellan AT, Cacciola JC, Alterman AI, Rikoon SH, Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. American Journal of Addiction. 2006;15(2):11.
34.
James JD, editor. Profile of jail inmates, 2002. Washington, DC: U.S. Department of Justice; 2004.
35.
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5).
36.
Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010;87(4):592–602.PubMedCrossRef
37.
Friedmann PD, Hoskinson R, Gordon M, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9–18.PubMedCrossRef
38.
Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8.PubMedCrossRef
39.
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2011;112(3):15.
40.
Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22–32.PubMedCrossRef
41.
Maslow AH. Toward a Pschology of Being. 3rd ed. New York: John Wiley and Sons; 1998.
42.
Wolitski RJ, Kidder DP, Pals SL, et al. Randomized trial of the effects of housing assistance on the health and risk behaviors of homeless and unstably housed people living with HIV. AIDS Behav. 2010;14(3):493–503.PubMedCrossRef
43.
Gelberg L, Gallagher TC, Andersen RM, Koegel P. Competing priorities as a barrier to medical care among homeless adults in Los Angeles. Am J Public Health. 1997;87(2):217–20.PubMedCrossRef
44.
Harris A, Selling D, Luther C, et al. Rate of community methadone treatment reporting at jail reentry following a methadone increased dose quality improvement effort. Subst Abus. 2012;33(1):70–5.PubMedCrossRef
45.
46.
47.
Metadata
Title
Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study
Authors
Archana Krishnan
Jeffrey A. Wickersham
Ehsan Chitsaz
Sandra A. Springer
Alison O. Jordan
Nick Zaller
Frederick L. Altice
Publication date
01-10-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue Special Issue 2/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0362-3

Other articles of this Special Issue 2/2013

AIDS and Behavior 2/2013 Go to the issue

Original Paper

Cost Analysis of Enhancing Linkages to HIV Care Following Jail: A Cost-Effective Intervention

Original Paper

Jails, HIV Testing, and Linkage to Care Services: An Overview of the EnhanceLink Initiative

Original Paper

Understanding the Revolving Door: Individual and Structural-Level Predictors of Recidivism Among Individuals with HIV Leaving Jail

Original Paper

Gender Differences in Baseline Health, Needs at Release, and Predictors of Care Engagement Among HIV-Positive Clients Leaving Jail

Original Paper

Jails as an Opportunity to Increase Engagement in HIV Care: Findings from an Observational Cross-Sectional Study

Commentary

Win–Win: How Health Care Professionals and Jail Administrators Can Collaborate to Address HIV Behind Bars
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits